Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 05 / 30 / 2020

Articles

A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01)

ORIGINAL ARTICLE

A Real-world Prospective Study of Mother-to-child Transmission of HBV in China Using a Mobile Health Application (Shield 01)

Xueru Yin1,  Guorong Han2, Hua Zhang3, Mei Wang4, Wenjun Zhang5, Yunfei Gao6, Mei ZhongHong6 Xiaolan Wang7, Xiaozhu Zhong8, Guojun Shen9,Chuangguo Yang10, Huiyuan Liu11, Zhihong Liu1,Po-Lin Chan12, Marc Bulterys13, Fuqiang Cui14, Hui Zhuang15, Zhihua Liu1,*, and Jinlin Hou1,*

1  Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
2  Department of Gynecology and Obstetrics, The Second Affiliated Hospital of the Southeast University, Nanjing, Jiangsu, China
3  Department of Obstetrics and Gynecology, Beijing Youan Hospital, Capital Medical University, Beijing, China
4  Department of Obstetrics and Gynecology, The Fifth Medical Centre, Chinese People’s Liberation Army General Hospital, Beijing, China
5  Department of Obstetrics and Gynecology, The Fifth Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China
6  Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
7  Department of Obstetrics, Jiujiang Maternal and Child Care Center, Jiujiang, Jiangxi, China
8  Department of Infectious Diseases, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
9  Department of Infectious Diseases, Third People’s Hospital of Jiujiang, Jiujiang, Jiangxi, China
10 Department of Infectious Diseases, The Third Affiliated Hospital of Southern Medical university, Guangzhou, Guangdong, China
11 Department of Severe Liver Diseases, Guangzhou Eighth People’s Hospital, Guangzhou, Guangdong, China
12 World Health Organization/Western Pacific Regional Office (WPRO), Manila, Philippines
13 Global Hepatitis Programme, World Health Organization, Geneva, Switzerland
14 School of Public Health, Peking University, Beijing, China
15 Department of Microbiology and Center of Infectious Diseases, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, China

*Correspondence to:Zhihua Liu, Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China. Tel: +86-20-62787432, Fax: +86-20-62786530, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; Jinlin Hou, Hepatology Unit, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China. Tel: +86-20-61641941, Fax: +86-20-62786530, .E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(1):1-8 DOI: 10.14218/JCTH.2019.00057
ReceivedDecember 14, 2019 Accepted: February 15, 2020 Published online: March 5, 2020

Abstract

Background and Aims: The World Health Organization (WHO) Western Pacific Region set a target of eliminating mother-to-child transmission (MTCT) of hepatitis B virus (HBV) by 2030. To assess the feasibility of this target in China, we carried out an epidemiological study to investigate the status quo of MTCT in the real-world setting.

Methods: One thousand and eight hepatitis B surface antigen-positive pregnant women were enrolled at 10 hospitals. Immunoprophylaxis was administered to infants. In addition, mothers with HBV DNA level >2,000,000 IU/mL were advised to initiate antiviral therapy during late pregnancy. A health application called SHIELD was used to manage the study.

Results: Nine hundred and five of the enrolled mothers, with 924 infants, completed the follow-up. Birth-dose hepatitis B vaccine and hepatitis B immunoglobulin were received by 99.7% and 99.7% of infants, respectively, within 24 h after birth. There were 446 mothers who received antiviral therapy, including 72.3% of the mothers with HBV DNA level >2,000,000 IU/mL and 21.0% of the mothers with HBV DNA level <2,000,000 IU/mL. Eight infants were infected with HBV. The overall rate of MTCT was 0.9%. Birth defects were rare (0.5% among infants with maternal antiviral exposure versus 0.7% among infants without exposure; p=1.00).

Conclusions: The MTCT rate was lower than the WHO Western Pacific Region elimination MTCT target in this real-world study, indicating that a comprehensive management composed of immunoprophylaxis to infants and antiviral prophylaxis to mothers may be a feasible strategy to achieve the 2030 WHO elimination goal.

Keywords

Mother-to-child transmission, Hepatitis B virus, Antiviral therapy, Immunoprophylaxis, Shield Project

 

Journal of Clinical and Translational Hepatology 2020 vol. 8, 1-8  [ Html ] [ PDF Full-text ]

 

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non-commercial and is otherwise in compliance with the license.

 

 

 logo

You are here: Home